Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients.
We evaluated the ability of fenoldopam, a newly available renal vasodilator, to prevent radiocontrast nephropathy in high-risk patients undergoing interventional diagnostic and therapeutic angiographic procedures. We reviewed the results from 46 consecutive procedures in patients with serum creatinine > or = 1.5 mg/dL if diabetic and > or = 1.7 mg/dL if nondiabetic. We compared our results to a previously published cohort of similarly at-risk patients. The incidence of radiocontrast nephropathy, defined as an increase in serum creatinine of > or = 25% at 48 hr following the procedure, was 13% in the group treated with fenoldopam, compared to an expected 38%. The percentage change in serum creatinine at 48 hr was +16% vs. +118%, respectively, in the two groups. In this preliminary experience, the use of fenoldopam in high-risk patients appears to minimize the likelihood of radioncontrast nephropathy. Cathet Cardiovasc Intervent 2001;53:341-345.
Madyoon
H
H
St. Joseph's Medical Center, 1800 N. California Street, Stockton, CA 95204, USA. cardiology@2xtreme.net
Croushore
L
L
Weaver
D
D
Mathur
V
V
D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography / Q000009:adverse effects; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005260:Female; D018818:Fenoldopam / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control*; D012189:Retrospective Studies; D014665:Vasodilator Agents / Q000627:therapeutic use*
D003287:Contrast Media; D014665:Vasodilator Agents; D003404:Creatinine; D018818:Fenoldopam